Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical News Today (MNT)3 Antidepressants May Be Best for Long-Term Depression Treatment

🧠 Mental Health / Behavioral Sensitivity

Long-term depression treatment involves both symptom relief and maintaining improvement. This consumer-facing article reports a systematic review comparing 20 antidepressants across 115 randomized trials involving more than 30,000 participants. Escitalopram, duloxetine, and agomelatine showed higher odds of sustained response than fluoxetine. Expert commentary places those findings alongside medical history, medication interactions, safety concerns, and patient goals. The article emphasizes that comparative effectiveness does not identify the best medication for every individual.


Patient Counseling Points

  • Compared with fluoxetine, sustained-response odds were 62% higher with escitalopram, 57% higher with duloxetine, and 40% higher with agomelatine.
  • The quoted psychiatrist describes escitalopram’s relatively low interaction burden and duloxetine’s potential relevance when depression coexists with chronic pain.
  • Agomelatine is not FDA approved; the article discusses liver injury concerns and its availability outside the United States.
  • Safety considerations include severely impaired kidney function with duloxetine, QT prolongation with escitalopram, and possible antidepressant-associated manic symptoms.
  • The article’s expert commentary supports continuing effective fluoxetine treatment and discussing partial or absent response with the treating clinician.

Patient Care Applications

  • The article clarifies that medication suitability also depends on symptoms, comorbidities, other prescriptions, substance use, and treatment history.
  • Its expert commentary recognizes differences in individual response despite the review’s comparative findings.
  • The discussion places patient goals alongside effectiveness and safety when describing how antidepressant choices are made.
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form